{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-014118","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.141841+00:00","generated_at":"2026-06-17T12:38:14.725614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PDS Biotech FY2022 net loss $40.9M; cash to Q3 2024; PDS0101 shows 100% response in cervical cancer","bullets":["Net loss for 2022 was $40.9M ($1.43/share) vs $16.9M ($0.66/share) in 2021; R&D expenses rose to $29.4M.","Cash balance of $73.8M as of Dec 31, 2022; management expects funds into Q3 2024.","FDA meeting supported registrational pathway for triple combo (PDS0101, PDS0301, ICI) in HPV+ cancers.","IMMUNOCERV trial: 100% clinical response (9/9 >60% tumor shrinkage) in high-risk cervical cancer patients.","Signed exclusive global license for PDS0301 from Merck KGaA for $10M ($5M cash + $5M in stock)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-014118","json":"https://secwatch.observer/filing/0001140361-23-014118.json","markdown":"https://secwatch.observer/filing/0001140361-23-014118.md","text":"https://secwatch.observer/filing/0001140361-23-014118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/0001140361-23-014118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/brhc10050432_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:38:14.725614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ad71341376e6b041719073305f129a29882a4c5","claim":"PDS Biotechnology Corp reported the year ended December 31, 2022 results: net income approximately $40.9 million, EPS $1.43 per basic share and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2022 was approximately $40.9 million, or $1.43 per basic share and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123014118/0001140361-23-014118-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"approximately $40.9 million"},{"label":"EPS","value":"$1.43 per basic share and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}